Suppr超能文献

[根据胃黏膜炎症病变程度评估幽门螺杆菌感染患者胃液中一氧化氮代谢产物]

[The assessment of nitric oxide metabolites in gastric juice in Helicobacter pylori infected subjects in compliance with grade of inflammatory lesions in gastric mucosa].

作者信息

Walecka-Kapica Ewa, Knopik-Dabrowicz Alina, Klupińska Grazyna, Chojnacki Jan

机构信息

Uniwersytet Medyczny w Łodzi, Klinika Gastroenterologii i Chorób Wewnetrznych.

出版信息

Pol Merkur Lekarski. 2008 Feb;24(140):95-100.

Abstract

UNLABELLED

The infection of H. pylori causes inflammatory lesions in gastric mucosa--until atrophic gastritis, intestinal metaplasia, dysplasia (precancerous states) and finally to gastric cancer or lymphoma. The mechanism of mentioned disturbances is complicated, no doubt that nitric oxide plays here very important role. It is proved, that H. pylori causes essential oxygen metabolism disturbances by activation of inflammatory infiltration's cells to oxide reactive forms as nitric oxide formation. Nitric oxide as oxide radical could react with other free radicals and contribute to oxidative lesions of gastric mucosa and alterations of its structure. The aim of the study was try to answer the question: 1. Is this the relationship between NO metabolites concentrations in gastric juice and morphological state of gastric mucosa? 2. Does H. pylori eradication influence on NO metabolites concentrations in gastric juice? 3. Does H. pylori eradication influence on grade of inflammatory lesions in gastric mucosa?

MATERIAL AND METHODS

The study included 75 subjects between of 21 to 60 years, infected with H. pylori with diagnosed (according to the Sydney system) different stages of chronic gastritis progression. The type of inflammation, activity, the presence of atrophy, intestinal metaplasia and H. pylori infection were assessed. The study group was divided into 3 subgroups: group I--25 subjects with chronic active gastritis, group II--25 subjects with chronic atrophic gastritis without intestinal metaplasia, group III--25 subjects with chronic atrophic gastritis with intestinal metaplasia. Control group comprised 20 healthy subjects, without H. pylori infection. In each patient during gastroscopy 5 biopsy specimens for histopathologic examination and for urea test and 3 ml gastric juice were collected. The concentration of nitric oxide metabolites in gastric juice was determined with spectrophotometric method, based on Griess reaction. H. pylori infection was detected using fast urea test (CLO--test), confirmed by histopathological examination (stained Giemsa method) and non-invasive urea breath test (UBT-13C). In H. pylori--infected patients the above mentioned investigations were performed three times -before, in 8 weeks and in 12 months after antibacterial treatment's finish. In antibacterial therapy we use 7-days three-drugs therapy (omeprasole, amoksycillin and clarythromycin).

RESULTS

The concentration of nitric oxide metabolites in gastric juice in healthy subjects was 6.81 +/- 2.23 micromol. In patients with chronic gastritis, H. pylori infected was significantly higher--in patients with chronic active gastritis was 9.29 +/- 2.19 micromol/l, in patients with chronic atrophic gastritis--10.25 +/- 2.31 micromol/l (p < 0.01), in patients with intestinal metaplasia--11.89 +/- 2.46 micromol/l (p < 0.01). 8 weeks after antibacterial treatment's finish the concentration of nitric oxide metabolites in gastric juice in each group decreased and were: in patients with chronic active gastritis was 8.18 +/- 1.63 micromol/l, in patients with chronic atrophic gastritis--10.02 +/- 2.28 micromol/l, in patients with intestinal metaplasia--10.83 +/- 2.32 micromol/l. The differences were not statistically significant. 12 months after antibacterial treatment's finish the concentration of nitric oxide metabolites in gastric juice in each group decreased and were: in patients with chronic active gastritis was 6.90 +/- 1.43 micromol/l, in patients with chronic atrophic gastritis--7.22 +/- 2.01 micromol/l, in patients with intestinal metaplasia--7.56 +/- 1.98 micromol/l. The differences were statistically significant--p < 0.05, p < 0.01. 8 weeks after antibacterial treatment's finish in each patient also the gastroscopy was performed and another biopsy specimen for histopathologic examination were collected. Only in group I in microscopic image the decreased of inflammation intensity was find (both in antrum and in corpus)--however the differences were not statistically significant. In the other groups the alterations in gastric mucosa do not improve significantly. The gastroscopy was performed again in 12 months after antibacterial treatment's finish. In group I the significant decrease or regression of inflammatory infiltration (in corpus and in antrum) was found. Also in group II the significant decrease of the grade of atrophy and similarly in III group the improvement of histopathological state were observed.

CONCLUSIONS

  1. The increase of NO metabolites concentration demonstrates positive correlation with grade of inflammatory lesions in gastric mucosa. 2. The effective antibacterial therapy causes the decrease of NO metabolites concentration in gastric juice, especially in patients with chronic active gastritis. 3. Eradication influence on decrease of grade of lesions' progression in gastric mucosa just in 12 months after effective antibacterial therapy.
摘要

未标注

幽门螺杆菌感染会导致胃黏膜出现炎症性病变,直至萎缩性胃炎、肠化生、发育异常(癌前状态),最终发展为胃癌或淋巴瘤。上述病变的机制很复杂,毫无疑问一氧化氮在其中起着非常重要的作用。已证实,幽门螺杆菌通过激活炎症浸润细胞形成一氧化氮等氧化反应性形式,导致基本的氧代谢紊乱。一氧化氮作为一种氧化自由基,可与其他自由基反应,导致胃黏膜的氧化损伤及其结构改变。本研究的目的是试图回答以下问题:1. 胃液中一氧化氮代谢产物浓度与胃黏膜形态状态之间是否存在关联?2. 根除幽门螺杆菌是否会影响胃液中一氧化氮代谢产物的浓度?3. 根除幽门螺杆菌是否会影响胃黏膜炎症病变的程度?

材料与方法

本研究纳入了75名年龄在21至60岁之间、感染幽门螺杆菌且诊断为(根据悉尼系统)不同阶段慢性胃炎进展的受试者。评估了炎症类型、活动度、萎缩、肠化生的存在情况以及幽门螺杆菌感染情况。研究组分为3个亚组:I组——25名慢性活动性胃炎患者,II组——25名无肠化生的慢性萎缩性胃炎患者,III组——25名有肠化生的慢性萎缩性胃炎患者。对照组包括20名未感染幽门螺杆菌的健康受试者。在每位患者进行胃镜检查时,采集5份活检标本用于组织病理学检查和尿素检测,并采集3毫升胃液。采用基于格里斯反应的分光光度法测定胃液中一氧化氮代谢产物的浓度。使用快速尿素检测(CLO检测)检测幽门螺杆菌感染,通过组织病理学检查(吉姆萨染色法)和非侵入性尿素呼气试验(UBT - 13C)进行确认。在幽门螺杆菌感染患者中,上述检查在抗菌治疗结束前、治疗后8周和12个月进行了三次。在抗菌治疗中,我们采用7天三联疗法(奥美拉唑、阿莫西林和克拉霉素)。

结果

健康受试者胃液中一氧化氮代谢产物的浓度为6.81±2.23微摩尔。在慢性胃炎患者中,幽门螺杆菌感染患者的浓度显著更高——慢性活动性胃炎患者为9.29±2.19微摩尔/升,慢性萎缩性胃炎患者为10.25±2.31微摩尔/升(p<0.01),肠化生患者为11.89±2.46微摩尔/升(p<0.01)。抗菌治疗结束8周后,每组胃液中一氧化氮代谢产物的浓度均下降,分别为:慢性活动性胃炎患者为8.18±1.63微摩尔/升,慢性萎缩性胃炎患者为10.02±2.28微摩尔/升,肠化生患者为10.83±2.32微摩尔/升。差异无统计学意义。抗菌治疗结束12个月后,每组胃液中一氧化氮代谢产物的浓度均下降,分别为:慢性活动性胃炎患者为6.90±1.43微摩尔/升,慢性萎缩性胃炎患者为7.22±2.01微摩尔/升,肠化生患者为7.56±1.98微摩尔/升。差异具有统计学意义——p<0.05,p<0.01。抗菌治疗结束8周后,对每位患者也进行了胃镜检查,并采集了另一份活检标本用于组织病理学检查。仅在I组的显微镜图像中发现炎症强度降低(在胃窦和胃体均有)——然而差异无统计学意义。其他组胃黏膜的改变没有明显改善。抗菌治疗结束12个月后再次进行胃镜检查。在I组中发现炎症浸润显著减少或消退(在胃体和胃窦)。在II组中也发现萎缩程度显著降低,同样在III组中观察到组织病理学状态有所改善。

结论

  1. 一氧化氮代谢产物浓度的升高与胃黏膜炎症病变程度呈正相关。2. 有效的抗菌治疗会导致胃液中一氧化氮代谢产物浓度降低,尤其是慢性活动性胃炎患者。3. 根除幽门螺杆菌仅在有效抗菌治疗12个月后对胃黏膜病变进展程度的降低有影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验